L-Lysine monohydrochloride is a feed additive produced by fermentation using a genetically modified strain of Escherichia coli (CGMCC 7.57). The Panel on Additives and Products or Substances used in Animal Feed (FEEDAP Panel) of the EFSA, in its opinion on the safety and efficacy of the product, could not conclude on the safety of the product for target animals, consumers, users and the environment. The European Commission asked EFSA to deliver an opinion on the safety of L-lysine monohydrochloride as a nutritional additive for all animal species based on additional data submitted by the applicant on the characterisation of the additive. No recombinant antibiotic resistance genes are present in the production strain and therefore in the final product. The L-lysine monohydrochloride manufactured by fermentation using E. coli CGMCC 7.57 does not raise safety concerns for the target species, consumers, users and the environment with regard to the genetic modification of the production strain. The levels of endotoxins present in the product and its dusting potential indicate no health risk for the user.
Summary
Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on L-lysine monohydrochloride produced by a genetically modified strain of Escherichia coli (CGMCC 7.57) for all animal species.
In 2015, the FEEDAP Panel of the European Food Safety Authority (EFSA) adopted an opinion on the safety and efficacy of L-lysine monohydrocloride produced by fermentation using E. coli CGMCC 7.57. In that opinion, the FEEDAP Panel could not conclude on the safety of the product for target animals, consumers, users and the environment.
The applicant provided additional information in relation to the characterisation of the additive and the production process. The FEEDAP Panel has performed the assessment of those new data following an approach in line with the principles laid down in Regulation (EC) No 429/2008 and the relevant guidance documents.
This product was characterised in a previous scientific opinion (EFSA FEEDAP Panel, 2015) . No recombinant antibiotic resistance genes are present in the production strain and therefore in the final product. The L-lysine monohydrochloride manufactured by fermentation using E. coli CGMCC 7.57 does not raise safety concerns for the target species, consumers, users and the environment with regard to the genetic modifications of the production strain.
The levels of endotoxins present in the product and its dusting potential indicate no health risk for the user. The applicant, Feedway Europe NV, is seeking a Community authorisation of L-lysine monohydrochloride (HCl) produced by fermentation with Escherichia coli to be used as a nutritional additive for all animal species. (Table 1) On 10 March 2015, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP Panel) of the European Food Safety Authority, in its opinion on the safety and efficacy of the product, could not conclude on the safety of the product L-lysine HCl produced by fermentation with this recombinant E. coli strain for target animals, consumers, users and the environment. Regardless of the assessment of the genetic modification, the FEEDAP Panel has concerns regarding the safety of the simultaneous oral administration of the product L-lysine HCl via water for drinking and feed. FEEDAP Panel has concerns that the safety of the genetic modification may also have implications for the safety of the user.
The Commission gave the possibility to the applicant to submit complementary information to complete the assessment on the safety and to allow a revision of Authority's opinion.
The Commission has now received new data on the safety of L-lysine monohydrochloride produced by Escherichia coli.
In view of the above, the Commission asks the Authority to deliver a new opinion on the safety of L-lysine monohydrochloride produced by fermentation with Escherichia coli as nutritional additive for all animal species based on the additional data submitted by the applicant.
1.2.
Additional information L-Lysine monohydrochloride (minimum content of L-lysine 78%, 'as is' basis) was first authorised for use in animal nutrition by Directive 88/485/EEC. It is currently included in the European Union as a nutritional additive (functional group amino acids, their salts and analogues) for use in all animal species without time limit and without maximum content in feed.
The applicant has provided additional information on the physical properties of the additive, the characterisation of the genetic modification and on the production process.
Although the additive was initially intended to be used in all animal species as a nutritional additive (functional group amino acids, their salts and analogues) in feed and water for drinking, during the assessment the applicant requested to withdraw the use of the additive in water for drinking. 
2.
Data and methodologies
Data
The present assessment is based on data submitted by the applicant in the form of a technical dossier 2 following a previous application on the same product. 
Assessment
The current application is for the authorisation of L-Lysine monohydrochloride produced by a genetically modified (GM) strain of E. coli (CGMCC 7.57) which is a derivative of E. coli K-12. It is intended to be used in all animal species as a nutritional additive (functional group amino acids, their salts and analogues) in feed.
Characterisation
This product has been characterised in a previous scientific opinion (EFSA FEEDAP Panel, 2015) with the exception of the genetic modification, for which the absence of antibiotic resistance genes in the production strain (and therefore in the product) was insufficiently proven.
Additional data have been submitted on the genetic modification process of the production strain, the physico-chemical properties of the additive and on its manufacturing process.
Impurities
The endotoxin activity in the former product (three batches analysed) ranged from 6.3 to 6.6 IU/mg. 5 An improvement in the manufacturing has been introduced in the downstream process to reduce the amount of bacterial endotoxins in the final product. The filtration by ceramic membrane has been modified (from a former pore size of 300 kDa to the current smaller size of 20 kDa) and reverse osmosis has been applied to reduce the amount of endotoxins in the process water. 6 New data have been submitted on the bacterial endotoxin activity of the product, measured in three batches. The values ranged from 0.12 to 0.28 IU/mg (European Pharmacopoeia 2.6.14 methods). 
Physical properties
The applicant stated that the production process had been modified to increase the crystal size of the final product and consequently decrease its dustiness. The evaporation temperature has been lowered (75-72°C), the evaporation rate reduced (2.5-2.0 m 3 /h), the evaporation time prolonged (12-15 h) and the cooling time extended from 3 to 5 h. 8 New analytical data have been provided to characterise the particle size and dustiness of the new final product. The particle size distribution (three batches analysed by laser diffraction) had a fraction of particles < 50 lm of diameter ranging from 0.2% to 1.2% (v/v) (mean particle diameter is about 600 lm).
9 In the former product (five batches analysed, method unknown), about 2.3% (w/w) of particles had a diameter < 50 lm.
10 The dusting potential (three batches analysed by the Stauber-Heubach method) ranged from 1.3 to 1.6 g/m 3 . 11 The dusting potential of the product assessed in 2015 (three batches) ranged from 1.8 to 2.1 g/m 3 .
3.1.3. Characterisation of the production strain E. coli CGMCC 7.57
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In the former assessment of the production strain (EFSA FEEDAP Panel, 2015) , no conclusive evidence was provided regarding the absence of antibiotic resistance genes (transiently used in the genetic modification) in the genome of the production strain or in the product.
The applicant has now provided analyses indicating that those genes are not present in the production strain. 
Safety
In its previous assessment (EFSA FEEDAP Panel, 2015) , the FEEDAP Panel could not conclude on the safety of the product L-lysine HCl produced by fermentation with this recombinant E. coli strain for target animals, consumers, users and the environment because the genetic modification, including the presence or absence of antibiotic resistance genes in the production strain (and therefore in the product), was insufficiently characterised.
The applicant has provided evidence that the production strain does not carry the antibiotic resistance genes transiently used during the genetic modification. Absence in the product of recombinant DNA corresponding to the inserted sequences was previously shown (EFSA FEEDAP Panel, 2015) . Therefore, L-lysine monohydrochloride manufactured by fermentation with E. coli CGMCC 7.57 does not raise any safety concern for the target animals, consumers, users and the environment with regard to the genetic modification of the production strain.
Safety for the user
In the previous opinion (EFSA FEEDAP Panel, 2015) , it was concluded that there was no concern for users with respect to skin or eye irritancy and dermal sensitisation. Nevertheless, the level of endotoxins present in the product and its dusting potential indicated an inhalation risk for the user. The concerns on the safety of the genetic modification may also have implications on safety for the user.
Effects on the respiratory system
Although a previous assessment was performed in March 2015 (EFSA FEEDAP Panel, 2015) , technological improvement in the manufacturing process makes it necessary to reassess the safety for the user when exposed by inhalation to the bacterial endotoxin activities found in the additive.
The bacterial endotoxin activity (the three new batches) ranges from 0.12 to 0.28 IU/mg. 15 The dusting potential ranges from 1.3 to 1.6 g/m 3 .
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The scenario used to estimate the exposure of persons handling the additive to endotoxins in the dust, based on the EFSA Guidance on user safety (2012b) is described in Appendix A. The healthbased recommended threshold for the quantity of inhaled endotoxins per working day is 900 IU, derived from provisional occupational exposure limits given by the Dutch Expert Committee on Occupational Safety (DECOS) (Health Council of the Netherlands, 2010) and the UK Health and Safety Executive (HSE, 2013) . Based on the calculation of the potential endotoxin content in dust (Wallace et al., 2016) , the inhalation exposure could be up to 246 endotoxin IU per 8-h working day, indicating no risk from the exposure to endotoxins for people handling the additive.
Conclusions on safety for the user
The additive L-lysine monohydrochloride is not a skin or eye irritant nor a skin sensitiser. The levels of endotoxins present in the product and its dusting potential indicate no health risk for the user.
does not raise safety concerns for the target species, consumers, users and the environment with regard to the genetic modification of the production strain.
The levels of endotoxins present in the product and its dusting potential indicate no health risk for the user. 
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